CClinicalTrials.gg
Status unknownNCT02451605Updated May 22, 2015

Regional Anesthesia for Knee Prothesis Surgery

An interventional study of Analgesic nerve blockade (Ropivacaine) and Total knee replacement surgery. in Total Knee Replacement, sponsored by University of Liege. Status unknown at 1 site in Belgium. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-22.

Sponsored by University of Liege · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2015), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Comparison of the analgesics blocks (femoral, adductor canal and sciatic subgluteal nerve) for total replacement knee surgery.

Read the detailed description

Adductor canal block shows a beneficial effect for knee surgery. Mainly because he prevent for muscular weakness; adverse effect meet with femoral block and delaying the early active mobilization.

The investigators want to compare the efficacy and safety of this block compared to the femoral and sciatic block.

02

Conditions studied

  • Total Knee Replacement

Keywords

  • surgery
03

In context

Lead sponsor

University of Liege is the lead sponsor of 242 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • patients scheduled for total knee replacement surgery.

Exclusion criteria

Exclusion Criteria:

  • refusal to study,
  • coagulation disorder,
  • infection at the puncture site,
  • preexisting neuropathy,
  • allergy to local anesthetics,
  • renal or hepatocellular insufficiency,
  • context of chronic pain,
  • drugs abuse,
  • pregnant patient.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Femoral nerve blockade

    In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.

    Drug: Analgesic nerve blockade (Ropivacaine) · Procedure: Total knee replacement surgery.

  • Active comparator
    Adductor canal blockade

    In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.

    Drug: Analgesic nerve blockade (Ropivacaine) · Procedure: Total knee replacement surgery.

  • Active comparator
    Subgluteal sciatic nerve blockade

    In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.

    Drug: Analgesic nerve blockade (Ropivacaine) · Procedure: Total knee replacement surgery.

Interventions

  • DrugAnalgesic nerve blockade (Ropivacaine)

    Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.

    Also known as: Regional anesthesia

  • ProcedureTotal knee replacement surgery.

    Total knee replacement surgery.

06

What researchers measure

Primary outcomes

  1. Pain measurement with numeric pain scale : from 0 to 10 (maximal pain) in rest condition

    Pain assessment and evolution in postoperative period (passive condition)

    Time frame: up to day 7

  2. Pain measurement with numeric pain scale (from 0 to 10) during active motorized mobilization (Kinetic)

    Pain assessment and evolution in postoperative period (active condition)

    Time frame: up to day 7

Secondary outcomes

  1. Postintervention nausea vomiting

    question : present or not

    Time frame: at hour 0, at hours 6, at day 1

  2. Patient satisfaction

    Questionnaire of patient felling and satisfaction. Choice within gradual felling : bad, middle, good, excellent

    Time frame: at day 1

  3. Opioid consumption

    doses of piritramid (synthetic opioid) administrated with patient control rescue analgesia device.

    Time frame: up to 48 hours

07

Study locations

1 site
  • University og Liege, University Hospital
    Liege, 4000, Belgium
    • Pierre Goffin · Contact · goffin.pjc@gmail.com · 003243667180
    • Jean Pierre Lecoq · Contact · jplecoq@chu.ulg.ac.be · 003243667180
    • Jean Pierre Lecoq, MD · Sub investigator
    • Philippe Gautier, MD · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02451605
Lead sponsor
University of Liege
Responsible party
Pierre Goffin (Clinical assistant, University of Liege) — Principal investigator
First posted
May 22, 2015
Start date
Jun 2015
Primary completion
Nov 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
May 22, 2015

Study contacts

Pierre Goffin
Contact
goffin.pjc@gmail.com
003243667178
Jean-Pierre Lecoq
Contact
jplecoq@chu.ulg.ac.be
003243667178
Jean-Francois Brichant
study chair · University of Liege

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion